Measuring the fetal zone of the adrenal gland is a better predictor of preterm birth than measuring cervical length, according to research presented at the Society For Maternal-Fetal Medicine Feb. 4.
Measuring the fetal zone of the adrenal gland is a better predictor of preterm birth than measuring cervical length, according to research presented at the Society For Maternal-Fetal Medicine Feb. 4.
Three-D adrenal gland volume is a very accurate predictor of preterm birth, said Dr. Ozhan Turan, the study's lead author. However, most people in the world don't have access to 3D ultrasound technology, so the researchers created measurements that can be done with 2D ultrasound.
More than 60 patients who had preterm labor symptoms at 23 to 37 weeks gestation were studied. The researchers measured 3D adrenal gland volume and 2D depth of the whole gland, which they divided by the fetal zone. Preterm birth occurred at less than seven days after assessment for 20 women while 42 delivered seven days or more after assessment. Cervical length was similar in both groups, but adrenal gland volume (3D) and depth of the whole gland divided by fetal zone (2D) were higher in the first group, an indication that measuring the adrenal gland is effective in identifying the likelihood of preterm birth.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Month, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.